Search
Quoin Pharmaceuticals Ltd
QNRXAdd to Watchlist
6.900USD
-0.070-1.00%
Close 09-10 16:00（ET）
486.44MMarket Cap
LossP/E TTM
After-hours (ET)0.000USD0.000
After-hours (ET)More Details of Quoin Pharmaceuticals Ltd Company
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Quoin Pharmaceuticals Ltd Profile
Ticker SymbolQNRX
Company nameQuoin Pharmaceuticals Ltd
IPO dateNov 01, 1989
CEOMyers (Michael)
Number of employees3
Security typeDepository Receipt
Fiscal year-endNov 01
Address23 Hata'as Street
CityKFAR SABA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code44425
Phone97299741444
Websitehttps://quoinpharma.com/
Ticker SymbolQNRX
IPO dateNov 01, 1989
CEOMyers (Michael)
Company Executives of Quoin Pharmaceuticals Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Michael Myers, Ph.D.
Dr. Michael Myers, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
37.71K
+54.33%
Ms. Sally Lawlor
Ms. Sally Lawlor
Chief Financial Officer
Chief Financial Officer
10.68K
+95.88%
Dr. Amotz Nehushtan
Dr. Amotz Nehushtan
Vice President - Research & Development & Product Development
Vice President - Research & Development & Product Development
--
--
Mr. Guy Sapir
Mr. Guy Sapir
Internal Auditor
Internal Auditor
--
--
Dr. Amos Ofer
Dr. Amos Ofer
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Mr. David L. Braun
Mr. David L. Braun
Independent Director
Independent Director
--
--
Mr. Jonathan Burgin, CPA
Mr. Jonathan Burgin, CPA
Independent External Director
Independent External Director
--
--
Ms. Ronit Biran
Ms. Ronit Biran
Independent Director
Independent Director
--
--
Mr. Yali Sheffi
Mr. Yali Sheffi
Independent External Director
Independent External Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Michael Myers, Ph.D.
Dr. Michael Myers, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
37.71K
+54.33%
Ms. Sally Lawlor
Ms. Sally Lawlor
Chief Financial Officer
Chief Financial Officer
10.68K
+95.88%
Dr. Amotz Nehushtan
Dr. Amotz Nehushtan
Vice President - Research & Development & Product Development
Vice President - Research & Development & Product Development
--
--
Mr. Guy Sapir
Mr. Guy Sapir
Internal Auditor
Internal Auditor
--
--
Dr. Amos Ofer
Dr. Amos Ofer
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Mr. David L. Braun
Mr. David L. Braun
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Quoin Pharmaceuticals Ltd?
The top five shareholders of Quoin Pharmaceuticals Ltd are: Dr. Michael Myers, Ph.D.
How many institutions hold shares of Quoin Pharmaceuticals Ltd (QNRX)?
As of 2026Q1, 40 institutions hold shares of Quoin Pharmaceuticals Ltd, with a combined market value of approximately 874.98K, accounting for 43.66% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 369388.00.